<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2c678496-2a12-3051-e063-6294a90a205e"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use LYMPHIR™ safely and effectively. See full prescribing information for LYMPHIR.
 <br/>
      <br/>
LYMPHIR™ (denileukin diftitox-cxdl) for injection, for intravenous use
 <br/>
Initial U.S. Approval: 2024
</title>
   <effectiveTime value="20250123"/>
   <setId root="ac3613d7-4304-40e7-a3f5-adb8a8adca5d"/>
   <versionNumber value="7"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="872692764"/>
            <name>Citius Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2c67c909-46dc-7e93-e063-6394a90aa8b8"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250123"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="52658-7777" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>LYMPHIR</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>denileukin diftitox-cxdl</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.2"/>
                              <denominator unit="mL" value="2"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.04"/>
                              <denominator unit="mL" value="2"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="3"/>
                              <denominator unit="mL" value="2"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="AE28F7PNPL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHIONINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="1.2"/>
                              <denominator unit="mL" value="2"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 20</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="100.4"/>
                              <denominator unit="mL" value="2"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7YIN7J07X4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TREHALOSE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="ug" value="300"/>
                              <denominator unit="mL" value="2"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="25E79B5CTM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DENILEUKIN DIFTITOX</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="25E79B5CTM" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DENILEUKIN DIFTITOX</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="2" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="52658-7777-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250301"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761312" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250301"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="2c678496-2a13-3051-e063-6294a90a205e"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: CAPILLARY LEAK SYNDROME</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Capillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold LYMPHIR until CLS resolves, or permanently discontinue based on severity
  
   <content styleCode="italics">[see Dosage and Administration (
   
    <linkHtml href="#_2_1__">2.1</linkHtml>,
   
    <linkHtml href="#_2_4__">2.4</linkHtml>) and Warnings and Precautions (
   
    <linkHtml href="#_5_1__">5.1</linkHtml>)]
  
   </content>.
 
  </content>
                  </paragraph>
               </text>
               <effectiveTime value="20240122"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: CAPILLARY LEAK SYNDROME</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <paragraph/>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">Capillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold LYMPHIR until CLS resolves or permanently discontinue based on severity. (
   
      <linkHtml href="#_2_1__">2.1</linkHtml>,
   
      <linkHtml href="#_2_4__">2.4</linkHtml>,
   
      <linkHtml href="#_5_1__">5.1</linkHtml>)
  
     </content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_1_indications_and">
               <id root="2c678496-2a14-3051-e063-6294a90a205e"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1 </content>
                  <content styleCode="bold">INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.</paragraph>
               </text>
               <effectiveTime value="20240117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>LYMPHIR is an IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. (
 
    <linkHtml href="#_1_indications_and">1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="2c678496-2a15-3051-e063-6294a90a205e"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2 </content>
                  <content styleCode="bold">DOSAGE AND ADMINISTRATION</content>
               </title>
               <text/>
               <effectiveTime value="20240815"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Delay start of treatment cycle if serum albumin level is below 3 g/dL. (
  
     <linkHtml href="#_2_1__">2.1</linkHtml>)
 
    </item>
                           <item>The recommended dosage of LYMPHIR is 9 mcg/kg/day actual body weight administered as an intravenous infusion on Days 1 through 5 of a 21-day cycle. (
  
     <linkHtml href="#_2_2__">2.2</linkHtml>)
 
    </item>
                           <item>Administer premedication as recommended. (
  
     <linkHtml href="#_2_3__">2.3</linkHtml>)
 
    </item>
                           <item>See full prescribing information for preparation and administration instructions. (
  
     <linkHtml href="#_2_5__">2.5</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_2_1__">
                     <id root="2c678496-2a16-3051-e063-6294a90a205e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.1 Important Dosing Instructions</content>
                     </title>
                     <text>
                        <paragraph>Prior to starting each treatment cycle, assess hepatic and renal function. If serum albumin is less than 3 g/dL, delay administration of LYMPHIR until serum albumin is greater than or equal to 3 g/dL
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#_5_1__">5.1</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240815"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_2__">
                     <id root="2c678496-2a17-3051-e063-6294a90a205e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.2 Recommended Dosage</content>
                     </title>
                     <text>
                        <paragraph>The recommended dosage of LYMPHIR is 9 mcg/kg/day actual body weight administered as an intravenous infusion over 60 minutes on Days 1 through 5 of a 21-day treatment cycle. Administer LYMPHIR until disease progression or unacceptable toxicity. </paragraph>
                     </text>
                     <effectiveTime value="20240117"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_3__">
                     <id root="2c678496-2a18-3051-e063-6294a90a205e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.3 Recommended Premedications</content>
                     </title>
                     <text>
                        <paragraph>Administer premedications prior to starting a LYMPHIR infusion in Cycles 1 through 3, as outlined in Table 1, to reduce the risk of infusion-related reactions
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#_5_3__">5.3</linkHtml>)]
 
  </content>.

 </paragraph>
                        <table ID="_Reft1">
                           <caption>Table 1. Premedication to be Administered to Patients Prior to LYMPHIR Infusion</caption>
                           <col width="120"/>
                           <col width="115"/>
                           <col width="200"/>
                           <col width="180"/>
                           <tbody>
                              <tr>
                                 <td scope="col" align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <content styleCode="bold"> Treatment 
      <br/>   Cycle
     </content>
                                 </td>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <content styleCode="bold"> Premedication</content>
                                 </td>
                                 <td scope="col" align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <content styleCode="bold">
                                       <content styleCode="bold"> Dosage</content>
                                    </content>
                                 </td>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <content styleCode="bold"> Administration</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="3" align="left" styleCode="Lrule Rrule Toprule" valign="bottom"> Cycles 1-3 
     <br/>   (optional   thereafter)
    </td>
                                 <td scope="row" align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Antipyretic</td>
                                 <td scope="col" align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Oral acetaminophen 650 mg 
     <br/>   or per local institutional 
     <br/>   guidelines 
    </td>
                                 <td align="left" styleCode="Lrule Rrule Toprule" valign="top"> At least 30 minutes 
     <br/>   prior to infusion 
    </td>
                              </tr>
                              <tr>
                                 <td scope="col" align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Antihistamine</td>
                                 <td scope="col" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Diphenhydramine 25 mg 
     <br/>   intravenously or other 
     <br/>   antihistamine per local 
     <br/>   institutional guidelines
    </td>
                                 <td scope="col" styleCode="Botrule Lrule Rrule Toprule" valign="top"> At least 30 minutes 
     <br/>   prior to infusion
    </td>
                              </tr>
                              <tr>
                                 <td scope="col" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Antiemetic</td>
                                 <td scope="col" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Per institutional guidelines</td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top"> At least 30 minutes 
     <br/>   prior to infusion
    </td>
                              </tr>
                              <tr>
                                 <td scope="col" align="left" styleCode="Botrule Lrule Rrule" valign="top"/>
                                 <td scope="col" align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"> Hydration</td>
                                 <td scope="col" styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph> 250 to 500 mL 0.9% Sodium 
      <br/>   Chloride Injection 
      <br/>   intravenously (or other 
      <br/>   amount of fluid considered to 
      <br/>   be most appropriate for the
     </paragraph>
                                    <paragraph> subject’s condition)</paragraph>
                                 </td>
                                 <td scope="col" styleCode="Botrule Lrule Rrule Toprule" valign="top"> At least 30 minutes 
     <br/>   prior to infusion
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>If patients experience a Grade 2 or higher infusion reaction, premedicate at least 30 minutes prior to each subsequent infusion with a systemic steroid such as dexamethasone 4 mg (or equivalent) via slow intravenous push, for at least 3 cycles.</paragraph>
                     </text>
                     <effectiveTime value="20240117"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_4__">
                     <id root="2c678496-2a19-3051-e063-6294a90a205e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.4 Dosage Modifications for Adverse Reactions</content>
                     </title>
                     <text>
                        <paragraph>Dosage modifications for adverse reactions with LYMPHIR are shown in Table 2 below.</paragraph>
                        <table ID="_Reft2">
                           <caption>Table 2: Recommended Dosage Modifications for Adverse Reactions</caption>
                           <col width="180"/>
                           <col width="110"/>
                           <col width="306"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Severity*</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">
                                       <content styleCode="bold">Dosage </content>Modification
    
     </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Lrule Rrule Toprule" valign="top">Capillary leak syndrome (CLS)
    
     <content styleCode="italics">[see Warnings and Precautions (
     
      <linkHtml href="#_5_1__">5.1</linkHtml>)]
    
     </content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top"> Grade 2</td>
                                 <td styleCode="Lrule Rrule Toprule">
                                    <list listType="unordered">
                                       <item>Withhold LYMPHIR until CLS resolves to Grade 1. </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top"> Grade 3</td>
                                 <td styleCode="Lrule Rrule Toprule">
                                    <list listType="unordered">
                                       <item>Withhold LYMPHIR and provide supportive care until CLS resolves to Grade 1.</item>
                                       <item>Resume LYMPHIR at 50% dose.</item>
                                       <item>Consider steroid premedication for subsequent infusions.</item>
                                       <item>Permanently discontinue upon recurrence.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule"/>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top"> Grade 4</td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <list listType="unordered">
                                       <item>Permanently discontinue LYMPHIR.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">Visual impairment
    
     <content styleCode="italics">[see Warnings and Precautions (
     
      <linkHtml href="#_5_2__">5.2</linkHtml>)]
    
     </content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top"> Grade 1 or 2</td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <list listType="unordered">
                                       <item>Consider withholding or discontinuing LYMPHIR as appropriate.</item>
                                       <item>Refer for ophthalmic evaluation.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule"/>
                                 <td styleCode="Lrule Rrule Toprule" valign="top"> Grade 3 or 4</td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <list listType="unordered">
                                       <item>Withhold LYMPHIR until resolved to Grade 1 or baseline.</item>
                                       <item>Refer for ophthalmic evaluation.</item>
                                       <item>Permanently discontinue LYMPHIR if impairment does not resolve to Grade 1 or baseline.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="top"> Infusion-related reactions
    
     <content styleCode="italics">[see Warnings and Precautions (
     
      <linkHtml href="#_5_3__">5.3</linkHtml>)]
    
     </content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top"> Grade 2 or 3</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <list listType="unordered">
                                       <item>Interrupt infusion and manage signs and symptoms.</item>
                                       <item>Administer steroid premedication prior to the subsequent doses of LYMPHIR 
      
       <content styleCode="italics">[see Dosage and Administration (
       
        <linkHtml href="#_2_3__">2.3</linkHtml>)]
      
       </content>
                                       </item>
                                       <item>Continue steroid premedication for each dose in the next 3 cycles and optional thereafter 
      
       <content styleCode="italics">[see Dosage and Administration (
       
        <linkHtml href="#_2_3__">2.3</linkHtml>)]
      
       </content>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top"/>
                                 <td styleCode="Lrule Rrule Toprule">
                                    <paragraph> Grade 4 or</paragraph>
                                    <paragraph> Recurrent</paragraph>
                                    <paragraph> Grade 3</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <list listType="unordered">
                                       <item> Permanently discontinue LYMPHIR.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">Hepatotoxicity
    
     <content styleCode="italics">[see Warnings and Precautions (
     
      <linkHtml href="#_5_4__">5.4</linkHtml>)]
    
     </content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule">
                                    <paragraph> Grade 2:   ALT/AST 3 to 
      <br/>   5 x upper limit 
      <br/>   of normal 
      <br/>   (ULN)
     </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <list listType="unordered">
                                       <item>Maintain LYMPHIR dose</item>
                                       <item>Monitor at least weekly until return to 
       <br/>  &lt; 3 x ULN
      </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"/>
                                 <td styleCode="Lrule Rrule Toprule" valign="top"> Grade 3: 
     <br/>   ALT/AST &gt; 5 
     <br/>   to 20 x ULN
    </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <list listType="unordered">
                                       <item>Withhold LYMPHIR and monitor at least weekly until return to &lt; 3 x ULN</item>
                                       <item>Resume LYMPHIR at same dose (first occurrence) or at a reduced dose (50%) for subsequent occurrence</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top"/>
                                 <td styleCode="Lrule Rrule Toprule"> Grade 4: 
     <br/>   ALT/AST &gt; 20 
     <br/>   x ULN
    </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <list listType="unordered">
                                       <item>Permanently discontinue LYMPHIR</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">Other Adverse Reactions
    
     <content styleCode="italics">[see Adverse Reactions (
     
      <linkHtml href="#_6_1__">6.1</linkHtml>)]
    
     </content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">Grade 3</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <list listType="unordered">
                                       <item>Withhold LYMPHIR until resolution of toxicity to Grade 1 or baseline.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule"/>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">Grade 4</td>
                                 <td styleCode="Lrule Rrule Toprule" valign="top">
                                    <list listType="unordered">
                                       <item>Permanently discontinue LYMPHIR as appropriate.</item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>* Based on NCI CTCAE version 5.0</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Restarting after Dosage Delay Due to Toxicity</content>
                        </paragraph>
                        <table border="1" cellspacing="0" cellpadding="0">
                           <col width="300"/>
                           <col width="300"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold"> Time Since the Last Dose Administered</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold"> Action for Next Dose</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph> Less than or equal to 16 days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph> Restart a new cycle no earlier than 16 
      <br/>   days after last dose of LYMPHIR
     </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph> More than 16 days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph> Restart a new cycle of LYMPHIR</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph> More than 42 days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph> Permanently discontinue LYMPHIR</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20240815"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_5__">
                     <id root="2c678496-2a1a-3051-e063-6294a90a205e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.5 </content>
                        <content styleCode="bold">Preparation and Administration</content>
                     </title>
                     <text>
                        <paragraph>Reconstitute and further dilute LYMPHIR prior to administration. Administer as an intravenous infusion over 60 minutes. Use aseptic technique to prepare LYMPHIR.</paragraph>
                        <paragraph>LYMPHIR does not contain a preservative or anti-microbial agent. Care should be taken during preparation and administration of LYMPHIR to prevent inadvertent microbial contamination.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Reconstitution</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>Calculate the dose (mcg), total volume (mL) of solution required, and number of vials of LYMPHIR needed based on the patient’s actual body weight (kg). More than one vial may be needed for a full dose.</item>
                           <item>Remove the vial(s) of LYMPHIR from the refrigerator and allow to stand for approximately 30 minutes to reach to room temperature [20°C to 25°C (68°F to 77°F)].</item>
                           <item>Reconstitute each LYMPHIR vial with 2.1 mL of Sterile Water for Injection to obtain a final concentration of 150 mcg/mL. If more than one vial is needed to make a complete dose, use a separate syringe and needle for each vial.</item>
                           <item>Gently swirl the vial. Do not shake.</item>
                           <item>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The reconstituted solution should be clear and colorless. Discard if the solution is not clear, colorless, and contains particulate matter.</item>
                           <item>Use the reconstituted LYMPHIR solution immediately to prepare the drug product. </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Dilution</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>Use only plastic syringes or soft plastic intravenous bags. Do
  
   <content styleCode="bold">not</content>use glass containers.
 
  </item>
                           <item>Maintain concentration of LYMPHIR at 15 mcg/mL or higher during all steps in the preparation of the solution for intravenous infusion.</item>
                           <item>Withdraw the calculated dose from the vial(s) with a sterile syringe and inject it into an empty intravenous bag.</item>
                           <item>Dilute with 0.9% Sodium Chloride Injection to final concentration of 15 mcg/mL or higher.</item>
                           <item>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if the prepared solution is cloudy or particulates are present.</item>
                           <item>If not used immediately, store the diluted LYMPHIR solution at room temperature [20°C to 25°C (68°F to 77°F)] for up to 4 hours. Protect diluted solution from light.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Administration</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>Administer infusion solution intravenously over 60 minutes through an intravenous line using a syringe pump or intravenous infusion bag. Do not administer through in-line filter.</item>
                           <item>Do not mix LYMPHIR with other drugs or administer other drugs through the same infusion line.</item>
                           <item>At the end of the infusion, discard any empty or unused portions of LYMPHIR immediately.</item>
                        </list>
                     </text>
                     <effectiveTime value="20240815"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_3_dosage_forms">
               <id root="2c678496-2a1b-3051-e063-6294a90a205e"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3 </content>
                  <content styleCode="bold">DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <paragraph styleCode="First Paragraph">For injection: 300 mcg/vial, sterile, white lyophilized cake in a single-dose vial for reconstitution and further dilution.</paragraph>
               </text>
               <effectiveTime value="20240815"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>For injection: 300 mcg lyophilized cake in a single-dose vial.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_4_contraindications">
               <id root="2c678496-2a1c-3051-e063-6294a90a205e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4 </content>
                  <content styleCode="bold">CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20240117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (
 
    <linkHtml href="#_4_contraindications">4</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_5_warnings">
               <id root="2c678496-2a1d-3051-e063-6294a90a205e"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5 </content>
                  <content styleCode="bold">WARNINGS AND</content>
                  <content styleCode="bold">PRECAUTIONS</content>
               </title>
               <text/>
               <effectiveTime value="20240815"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Visual Impairment: Monitor and evaluate for visual impairment throughout treatment. Withhold LYMPHIR until visual impairment resolves or permanently discontinue based on severity. (
  
     <linkHtml href="#_5_2__">5.2</linkHtml>)
 
    </item>
                           <item>Infusion-Related Reactions: Monitor patients closely during infusions. Interrupt or discontinue for infusion-related reactions based on severity. (
  
     <linkHtml href="#_5_3__">5.3</linkHtml>)
 
    </item>
                           <item>Hepatotoxicity: Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. (
  
     <linkHtml href="#_5_4__">5.4</linkHtml>)
 
    </item>
                           <item>Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. (
  
     <linkHtml href="#_5_5__">5.5</linkHtml>,
  
     <linkHtml href="#_8_1__">8.1</linkHtml>,
  
     <linkHtml href="#_8_3__">8.3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_5_1__">
                     <id root="2c678496-2a1e-3051-e063-6294a90a205e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.1 Capillary Leak Syndrome</content>
                     </title>
                     <text>
                        <paragraph>LYMPHIR can cause capillary leak syndrome (CLS), including life-threatening or fatal reactions. CLS was defined in the clinical trials as the occurrence of at least 2 of the following symptoms at any time during LYMPHIR therapy: hypotension, edema, and serum albumin &lt;3 g/dL. These symptoms were not required to occur simultaneously to be characterized as capillary leak syndrome.</paragraph>
                        <paragraph>As defined, CLS occurred in 27% of patients in the pooled population across 3 clinical trials, including 8% with Grade 3. There was one (0.8%) fatal occurrence of CLS. Of the patients with CLS, 22% had recurrence. The majority of CLS events (81%) occurred within the first 2 cycles of treatment. The median time to onset from Cycle 1, Day 1 was 6.5 days (range: 1 to 77), the median duration of CLS was 14 days (range: 2 to 40), and 75% of patients had resolution. The most common symptoms included edema, hypoalbuminemia, and hypotension. Pleural effusion, pericardial effusion, and dehydration also occurred.</paragraph>
                        <paragraph>Regularly assess patients for weight gain, new onset or worsening of edema, dyspnea, and hypotension (including orthostatic changes). Monitor serum albumin levels prior to the initiation of each cycle of therapy and more often as clinically indicated.</paragraph>
                        <paragraph>Withhold, reduce dose, or permanently discontinue based on severity. If LYMPHIR is withheld, resume LYMPHIR following resolution of CLS and when serum albumin is greater than or equal to 3 g/dL
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#_2_1__">2.1</linkHtml>and
  
   <linkHtml href="#_2_4__">2.4</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240815"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_2__">
                     <id root="2c678496-2a1f-3051-e063-6294a90a205e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.2 Visual Impairment</content>
                     </title>
                     <text>
                        <paragraph>LYMPHIR can cause serious visual impairment, including changes in visual acuity and color vision. In the pooled population across 3 clinical trials, visual impairment occurred in 9%, with Grade 1 in 8% and Grade 2 in 1%. The most commonly reported symptom was blurred vision. Of the patients with visual impairment, 67% had resolution of their visual impairment.</paragraph>
                        <paragraph>Perform baseline ophthalmic examination and monitor as clinically indicated. If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision, or blurred vision, refer for ophthalmologic evaluation.</paragraph>
                        <paragraph>Withhold LYMPHIR until visual impairment resolves or permanently discontinue based on severity
 
  <content styleCode="italics">
                              <content styleCode="italics">[see Dosage and Administration </content>(
  
   <linkHtml href="#_2_4__">2.4</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240815"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_3__">
                     <id root="2c678496-2a20-3051-e063-6294a90a205e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.</content>
                        <content styleCode="bold">3 Infusion-Related Reactions</content>
                     </title>
                     <text>
                        <paragraph>LYMPHIR can cause serious infusion-related reactions. Infusion-related reactions were reported in 69% of patients in the pooled population across 3 clinical trials of patients who received LYMPHIR, with Grade 3 infusion-related reactions in 3.4%
 
  <content styleCode="italics">[see Adverse Reactions (
  
   <linkHtml href="#_6_1__">6.1</linkHtml>)]
 
  </content>. Eighty-three percent of infusion-related reactions occurred in Cycles 1 and 2. The most common symptoms included nausea, fatigue, chills, musculoskeletal pain, vomiting, fever, and arthralgia.

 </paragraph>
                        <paragraph>Premedicate patients for the first three cycles prior to starting a LYMPHIR infusion
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#_2_3__">2.3</linkHtml>)]
 
  </content>. Monitor patients frequently during infusion. For Grade 2 or higher infusion reactions, premedicate at least 30 minutes prior to each subsequent infusion with a systemic steroid for at least 3 cycles
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#_2_3__">2.3</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>Interrupt or discontinue LYMPHIR based on severity
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#_2_4__">2.4</linkHtml>)].
 
  </content>Institute appropriate medical management.

 </paragraph>
                     </text>
                     <effectiveTime value="20240815"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_4__">
                     <id root="2c678496-2a21-3051-e063-6294a90a205e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.</content>
                        <content styleCode="bold">4 Hepatotoxicity</content>
                     </title>
                     <text>
                        <paragraph>LYMPHIR can cause hepatotoxicity. In the pooled safety population, elevated ALT occurred in 70% of patients, with Grade 3 ALT occurring in 22%; elevated AST occurred in 64% of patients, with Grade 3 AST elevation occurring in 9%. For Grade 3 events, median time to onset was 8 days (range: 1 to 15 days); median time to resolution was 15 days (range: 7 to 50 days); all cases of Grade 3 ALT or AST elevations resolved
 
  <content styleCode="italics">[see Adverse Reactions (
  
   <linkHtml href="#_6_1__">6.1</linkHtml>)].
 
  </content>Elevated total bilirubin occurred in 5% of patients, with Grade 3 occurring in 0.9%.

 </paragraph>
                        <paragraph>Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold, reduce dose, or permanently discontinue LYMPHIR based on severity
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#_2_4__">2.4</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240815"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_5__">
                     <id root="2c678496-2a22-3051-e063-6294a90a205e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.5 Embryo-Fetal Toxicity</content>
                     </title>
                     <text>
                        <paragraph>Based on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman. Verify the pregnancy status of females of reproductive potential prior to the initiation of LYMPHIR. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 7 days following the last dose of LYMPHIR
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#_8_1__">8.1</linkHtml>,
  
   <linkHtml href="#_8_3__">8.3</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_6_adverse">
               <id root="2c678496-2a23-3051-e063-6294a90a205e"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6 </content>
                  <content styleCode="bold">ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph styleCode="First Paragraph">The following adverse reactions are discussed in greater detail in other sections of the label:</paragraph>
                  <list listType="unordered">
                     <item>Capillary Leak Syndrome
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#_5_1__">5.1</linkHtml>)]
  
   </content>
                     </item>
                     <item>Visual Impairment
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#_5_2__">5.2</linkHtml>)]
  
   </content>
                     </item>
                     <item>Infusion-Related Reactions
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#_5_3__">5.3</linkHtml>)]
  
   </content>
                     </item>
                     <item>Hepatotoxicity
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#_5_4__">5.4</linkHtml>)]
  
   </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (≥20%), including laboratory abnormalities, are increased transaminases, albumin decreased, nausea, edema, hemoglobin decreased, fatigue, musculoskeletal pain, rash, chills, constipation, pyrexia, and capillary leak syndrome. (
 
    <linkHtml href="#_6_1__">6.1</linkHtml>)

   </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Citius Oncology, Inc. at 1-844-459-6744 or FDA at 1-800-FDA-1088 or
  
     <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>.
 
    </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_6_1__">
                     <id root="2c678496-2a24-3051-e063-6294a90a205e"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.1 </content>
                        <content styleCode="bold">Clinical Trials Experience</content>
                     </title>
                     <text>
                        <paragraph styleCode="First Paragraph">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to LYMPHIR as a single agent in 119 patients with CTCL across 3 clinical trials. Patients received treatment with LYMPHIR as an intravenous infusion at 9 mcg/kg daily from Day 1 through Day 5 of each 21-day cycle until disease progression or unacceptable toxicity. Among 119 patients who received LYMPHIR the median number of cycles received was 5 (range: 1 to 42), with 13% exposed for 6 months or longer.</paragraph>
                        <paragraph styleCode="Paragraph">In this pooled safety population, the most common (≥ 20%) adverse reactions, including laboratory abnormalities, were increased transaminases (70%), albumin decreased (53%), nausea (40%), edema (35%), hemoglobin decreased (34%), fatigue (30%), musculoskeletal pain (26%), rash (23%), chills (22%), constipation (22%), pyrexia (21%), and capillary leak syndrome (20%).</paragraph>
                        <paragraph styleCode="Paragraph">
                           <content styleCode="underline">Relapsed or Refractory Stage I-III CTCL</content>
                        </paragraph>
                        <paragraph styleCode="Paragraph">
                           <content styleCode="italics">Study 302</content>
                        </paragraph>
                        <paragraph styleCode="Paragraph">The safety of LYMPHIR was evaluated in Study 302, an open-label, single-arm, multicenter trial that included 69 patients with relapsed or refractory Stage I-III CTCL
 
  <content styleCode="italics">[see Clinical Studies (
  
   <linkHtml href="#_14_clinical">14</linkHtml>)]
 
  </content>. Patients received treatment with LYMPHIR 9 mcg/kg daily from Day 1 through Day 5 of each 21-day cycle. Treatment was administered until disease progression or unacceptable toxicity. The median number of LYMPHIR cycles was 6 (range: 1 to 42).

 </paragraph>
                        <paragraph styleCode="Paragraph">The median age of patients was 64 years (range: 28 to 87 years), 49% were 65 years of age or older, 65% were men, 72% were White, 19% were Black or African American, 1.4% were Asian, and 14% were Hispanic or Latino.</paragraph>
                        <paragraph styleCode="Paragraph">Serious adverse reactions occurred in 38% of patients who received LYMPHIR. Serious adverse reactions in &gt; 2% of patients included capillary leak syndrome (10%), infusion-related reaction (9%), sepsis (7%), skin infection (2.9%), pyrexia (2.9%), and rash (2.9%).</paragraph>
                        <paragraph styleCode="Paragraph">Permanent discontinuation of LYMPHIR due to an adverse reaction occurred in 12% of patients. Adverse reactions resulting in permanent discontinuation of LYMPHIR included capillary leak syndrome, infusion-related reaction, renal insufficiency, respiratory failure, and sepsis.</paragraph>
                        <paragraph styleCode="Paragraph">Dosage interruptions of LYMPHIR due to an adverse reaction occurred in 38% of patients. Adverse reactions requiring dosage interruption of LYMPHIR included capillary leak syndrome, infusion-related reaction, weight increase, nausea, and tachycardia.</paragraph>
                        <paragraph styleCode="Paragraph">Table 3 summarizes the adverse reactions in Study 302.</paragraph>
                        <table ID="_Reft3">
                           <caption>Table 3: Adverse Reactions (≥ 10%) in Patients with Relapsed or Refractory Stage I-III CTCL Who Received LYMPHIR in Study 302</caption>
                           <col width="256"/>
                           <col width="181"/>
                           <col width="162"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td colspan="2" align="center" styleCode="Lrule Rrule Toprule">
                                    <paragraph>
                                       <content styleCode="bold">LYMPHIR</content>
                                    </paragraph>
                                    <content styleCode="bold">N=69</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule"/>
                                 <td align="center" styleCode="Lrule Rrule Toprule">
                                    <paragraph>
                                       <content styleCode="bold">All Grades</content>
                                    </paragraph>
                                    <content styleCode="bold">(%)</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">
                                    <paragraph>
                                       <content styleCode="bold">Grade 3 or 4</content>
                                    </paragraph>
                                    <content styleCode="bold">(%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Nausea</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">43</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1.4
    
     <sup>﻿#</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Diarrhea</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">19</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Vomiting</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">13</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Constipation</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">12</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">General disorders and administration site conditions</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Fatigue
    
     <sup>a</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">38</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Edema
    
     <sup>b</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">33</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1.4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Chills</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">27</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1.4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Pyrexia</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">16</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1.4</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Musculoskeletal pain
    
     <sup>c</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">27</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">2.9</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Arthralgia</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">12</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Nervous system disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Headache
    
     <sup>d</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">25</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Dizziness</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">13</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Mental status changes
    
     <sup>e</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">13</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Injury, poisoning and procedural complications</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Infusion-related reaction</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">25</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">6</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Rash
    
     <sup>f</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">23</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Pruritis</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">19</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">6</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Vascular disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Capillary leak syndrome</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">17</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">6</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Metabolism and nutrition disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Decreased appetite</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">13</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1.4</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Eye disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Blurred vision</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">13</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Investigations</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Weight increased</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">13</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Infections and infestations</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Skin infection
    
     <sup>g</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">13</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1.4</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Renal and urinary disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Renal insufficiency
    
     <sup>h</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">12</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">2.9</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Psychiatric disorders</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule"/>
                                 <td align="center" styleCode="Lrule Rrule Toprule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Insomnia</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">10</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>#</sup>Only Grade 3 adverse reaction occurred 
  <br/>
                           <sup>a</sup>Includes fatigue, asthenia, and lethargy 
  <br/>
                           <sup>b</sup>Includes edema, edema peripheral, generalized edema, face edema, swelling face, peripheral swelling 
  <br/>
                           <sup>c</sup>Includes musculoskeletal pain, back pain, neck pain, pain in extremity, myalgia, bone pain 
  <br/>
                           <sup>d</sup>Includes headache, migraine 
  <br/>
                           <sup>e</sup>Includes amnesia, confusional state, delirium, memory impairment, disturbance in attention, somnolence, cognitive disorder 
  <br/>
                           <sup>f</sup>Includes rash, drug eruption, erythema, rash maculo-papular, rash papular, rash pustular, rash pruritic, dermatitis exfoliative generalized, acute generalized exanthematous pustulosis 
  <br/>
                           <sup>g</sup>Includes skin infection, skin bacterial infection, staphylococcal skin infection, impetigo 
  <br/>
                           <sup>h</sup>Includes acute kidney injury, blood creatinine increased

 </paragraph>
                        <paragraph styleCode="Paragraph"/>
                        <paragraph styleCode="Paragraph">Clinically relevant adverse reactions in &lt; 10% of patients who received LYMPHIR included sepsis and peripheral neuropathy.</paragraph>
                        <paragraph styleCode="Paragraph">Table 4 summarizes select laboratory abnormalities in Study 302.</paragraph>
                        <table ID="_Reft4">
                           <caption>Table 4: Select Laboratory Abnormalities (≥ 10%) that Worsened from Baseline in Patients with Relapsed or Refractory Stage I-III CTCL who Received LYMPHIR in Study 302</caption>
                           <col width="252"/>
                           <col width="132"/>
                           <col width="132"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="bottom">
                                    <content styleCode="bold">Laboratory Abnormality
     
      <sup>a,b</sup>
                                    </content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="bottom">
                                    <content styleCode="bold">Any Grade
     
      <sup>c</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">(%)
     
      <sup>b</sup>
                                    </content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule" valign="bottom">
                                    <content styleCode="bold">Grade 3 or 4
     
      <sup>c</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">(%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Chemistry</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Alanine aminotransferase increased</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">66</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">13</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Aspartate aminotransferase increased</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">60</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">4.5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Albumin decreased </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">43</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1.5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Creatine phosphokinase increased
    
     <sup>d</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">22</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Alkaline phosphatase increased</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">18</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">0</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Hematology</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Lymphocyte count decreased</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">52</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">20</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Hemoglobin decreased</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">34</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1.5</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a</sup>Graded according to NCI CTCAE version 5.0 
  <br/>
                           <sup>b</sup>The denominator used to calculate the rate was 67 based on the number of patients with a baseline value and at least one post-treatment value 
  <br/>
                           <sup>c</sup>Percentage of patients with an increase of at least 1 CTCAE grade from baseline to the worst post-baseline value of any grade, or to the worst post-baseline value that is Grade 3 or 4 
  <br/>
                           <sup>d</sup>The denominator used to calculate the rate was based on 36 patients with a baseline value and at least one post-treatment value.

 </paragraph>
                     </text>
                     <effectiveTime value="20240815"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2c678496-2a25-3051-e063-6294a90a205e"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.</content>
                        <content styleCode="bold">2 </content>
                        <content styleCode="bold">Postmarketing Experience</content>
                     </title>
                     <text>
                        <paragraph styleCode="First Paragraph">The following adverse reactions have been identified during post-approval use of denileukin diftitox. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <list listType="unordered">
                           <item>Thyroid conditions: hyperthyroidism, thyroiditis, thyrotoxicosis, and hypothyroidism.</item>
                        </list>
                     </text>
                     <effectiveTime value="20240117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_8_specific">
               <id root="2c678496-2a26-3051-e063-6294a90a205e"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8 </content>
                  <content styleCode="bold">USE IN SPECIFIC POPULATIONS</content>
               </title>
               <text/>
               <effectiveTime value="20240117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Lactation:</content>Advise not to breastfeed. (
 
    <linkHtml href="#_8_2__">8.2</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_8_1__">
                     <id root="2c678496-2a27-3051-e063-6294a90a205e"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">8.1 </content>
                        <content styleCode="bold">Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Based on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman
 
  <content styleCode="italics">[see Clinical Pharmacology (
  
   <linkHtml href="#_12_1__">12.1</linkHtml>)].
 
  </content>There are no available data on the use of LYMPHIR in pregnant women to evaluate for a drug-associated risk. No animal reproductive and developmental toxicity studies have been conducted with denileukin diftitox.

 </paragraph>
                        <paragraph>Denileukin diftitox-cxdl causes depletion of regulatory T lymphocytes (Treg), immune activation, and capillary leak syndrome, compromising pregnancy maintenance. Advise pregnant women of the potential risk to a fetus.</paragraph>
                        <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respectively. </paragraph>
                     </text>
                     <effectiveTime value="20240117"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_2__">
                     <id root="2c678496-2a28-3051-e063-6294a90a205e"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>
                        <content styleCode="bold">8.</content>
                        <content styleCode="bold">2 </content>
                        <content styleCode="bold">Lactation</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>No data are available regarding the presence of denileukin diftitox-cxdl in human milk, the effects on the breastfed child, or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with LYMPHIR and for 7 days after the last dose.</paragraph>
                     </text>
                     <effectiveTime value="20240117"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_3__">
                     <id root="2c678496-2a29-3051-e063-6294a90a205e"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>
                        <content styleCode="bold">8.3 </content>
                        <content styleCode="bold">Females and Males of Reproductive Potential</content>
                     </title>
                     <text>
                        <paragraph>Based on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#_8_1__">8.1</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Testing</content>
                        </paragraph>
                        <paragraph>Verify the pregnancy status of females of reproductive potential prior to initiating LYMPHIR
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#_8_1__">8.1</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Females</content>
                        </paragraph>
                        <paragraph>Advise females of reproductive potential to use effective contraception during treatment with LYMPHIR and for 7 days after the last dose.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Based on findings in rats, male fertility may be compromised by treatment with LYMPHIR
 
  <content styleCode="italics">[see Nonclinical Toxicology (
  
   <linkHtml href="#_13_1__">13.1</linkHtml>)]
 
  </content>. The reversibility of the effect on fertility is unknown.

 </paragraph>
                     </text>
                     <effectiveTime value="20240117"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2c678496-2a2a-3051-e063-6294a90a205e"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.4 </content>
                        <content styleCode="bold">Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>Safety and effectiveness of LYMPHIR in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20240117"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2c678496-2a2b-3051-e063-6294a90a205e"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.5 </content>
                        <content styleCode="bold">Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>Of the 69 patients with Stage I-III relapsed or refractory CTCL who received LYMPHIR, 34 patients (49%) were 65 years of age and older and 10 patients (14%) were 75 years of age and older
 
  <content styleCode="italics">[see Clinical Studies (
  
   <linkHtml href="#_14_clinical">14</linkHtml>)]
 
  </content>. Clinical studies of LYMPHIR did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.

 </paragraph>
                     </text>
                     <effectiveTime value="20240117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_11_description">
               <id root="2c678496-2a2c-3051-e063-6294a90a205e"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11 </content>
                  <content styleCode="bold">DESCRIPTION</content>
               </title>
               <text>
                  <paragraph styleCode="First Paragraph">Denileukin diftitox-cxdl, an IL2-receptor-directed cytotoxin, is a recombinant DNA-derived fusion protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met
 
  <sub>1</sub>-Thr
 
  <sub>387</sub>)-His and the sequence for human interleukin-2 (IL-2; Ala
 
  <sub>1</sub>-Thr
 
  <sub>133</sub>). It is produced in an
 
  <content styleCode="italics">E. coli</content>expression system and has a molecular weight of 58 kD. Neomycin is used in the fermentation process but is undetectable in the final product.

 </paragraph>
                  <paragraph styleCode="Paragraph">LYMPHIR (denileukin diftitox-cxdl) for injection is supplied as a sterile, white, lyophilized cake in a single-dose vial for intravenous use after reconstitution and dilution. Each vial of LYMPHIR contains 300 mcg of denileukin diftitox-cxdl, citric acid monohydrate (4.2 mg), edetate disodium (0.04 mg), methionine (3 mg), polysorbate 20 (1.2 mg), and trehalose (100.4 mg). Sodium hydroxide is used to adjust the pH of the formulation buffer. Following reconstitution with 2.1 mL of Sterile Water for Injection, USP, the resulting concentration of denileukin diftitox-cxdl is 150 mcg/mL at pH approximately 7.</paragraph>
               </text>
               <effectiveTime value="20240815"/>
            </section>
         </component>
         <component>
            <section ID="_12_clinpharm">
               <id root="2c678496-2a2d-3051-e063-6294a90a205e"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12 </content>
                  <content styleCode="bold">CLINICAL PHARMACOLOGY</content>
               </title>
               <text/>
               <effectiveTime value="20240117"/>
               <component>
                  <section ID="_12_1__">
                     <id root="2c678496-2a2e-3051-e063-6294a90a205e"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1 </content>
                        <content styleCode="bold">Mechanism of Action</content>
                     </title>
                     <text>
                        <paragraph>Denileukin diftitox-cxdl is a fusion protein designed to direct the cytocidal action of diphtheria toxin (DT) to cells which express the IL-2 receptor. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing tumors.</paragraph>
                     </text>
                     <effectiveTime value="20240815"/>
                  </section>
               </component>
               <component>
                  <section ID="_12_2__">
                     <id root="2c678496-2a2f-3051-e063-6294a90a205e"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.2</content>
                        <content styleCode="bold"/>
                        <content styleCode="bold">Pharmacodynamics</content>
                     </title>
                     <text>
                        <paragraph>Higher denileukin diftitox-cxdl exposures were associated with higher incidence of capillary leak syndrome, hepatotoxicity, treatment discontinuations due to adverse reactions, and adverse reactions Grade ≥3 following administration of LYMPHIR. Denileukin diftitox-cxdl time course of pharmacodynamic response is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20240117"/>
                  </section>
               </component>
               <component>
                  <section ID="_12_3__">
                     <id root="2c678496-2a30-3051-e063-6294a90a205e"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.</content>
                        <content styleCode="bold">3 </content>
                        <content styleCode="bold">Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>Following a single dose of denileukin diftitox-cxdl 9 mcg/kg via 1-hr infusion on Cycle 1, Day 1 in patients with CTCL, the geometric mean (coefficient of variation [CV]%) maximum serum concentration (C
 
  <sub>max</sub>) was 94.4 ng/mL (77%) and area under the concentration over time curve (AUC
 
  <sub>0-inf</sub>) was 20700 ng· min/L (60%). There is no accumulation after repeated daily dosing.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>The geometric mean (CV%) volume of distribution of denileukin diftitox-cxdl is 5.0 L (43%) on Cycle 1, Day 1.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>The geometric mean (CV%) clearance is 36.5 mL/min (73%) after the first dose of denileukin diftitox-cxdl at the recommended dose level. The arithmetic mean (CV%) denileukin diftitox-cxdl terminal half-life is 112 minutes (31%) on Cycle 1, Day 1.  </paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism</content>
                        </paragraph>
                        <paragraph>Denileukin diftitox-cxdl is expected to be metabolized into small peptides by catabolic pathways.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>No clinically significant differences in the pharmacokinetics of LYMPHIR were observed based on age (23 to 86 years), body weight (39 kg to 148 kg), sex, race (White, African American/Black, Asian), ECOG status (0 to 2), mild to moderate renal impairment (estimated creatinine clearance [CLcr] by Cockcroft–Gault equation: 30 to 89 mL/min), or mild hepatic impairment (total bilirubin less than or equal to upper limit of normal [ULN] and AST greater than ULN, or total bilirubin 1 to 1.5 times ULN and any AST). The effect of moderate or severe hepatic impairment (total bilirubin greater than 1.5 times ULN with any AST) and severe renal impairment (CLcr 15 to 29 mL/min) on denileukin diftitox-cxdl pharmacokinetics is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20240815"/>
                  </section>
               </component>
               <component>
                  <section ID="_12_6__">
                     <id root="2c678496-2a31-3051-e063-6294a90a205e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">12.6</content>
                        <content styleCode="bold"/>
                        <content styleCode="bold">Immunogenicity</content>
                     </title>
                     <text>
                        <paragraph>The observed incidence of anti-drug antibodies (ADAs) is highly dependent on the sensitivity and specificity of the methods. Differences in ADA assay methods may preclude meaningful comparisons of the incidence of ADAs in the studies of denileukin diftitox-cxdl.</paragraph>
                        <paragraph/>
                        <paragraph>In Study 302, among patients with any stage CTCL who received LYMPHIR 9 mcg/kg/day (median duration of treatment: 6 cycles),</paragraph>
                        <list listType="unordered">
                           <item>Of the 90 subjects with immunogenicity results at baseline, 74% (67/90) of subjects had pre-existing antibodies to denileukin diftitox-cxdl and 7.8% (7/90) of the subjects had neutralizing anti-denileukin diftitox-cxdl antibodies. The high prevalence of ADA at baseline was anticipated due to vaccination against diphtheria toxin. Among these subjects, 5.6% (5/90) of the subjects had ADAs against IL-2 but none had neutralizing antibodies against IL-2.</item>
                           <item>Of the 84 subjects evaluable for treatment-emergent (TE) ADA across all cycles after treatment with LYMPHIR, 88% (74/84) and 82% (69/84) of subjects developed treatment-emergent ADAs against denileukin diftitox-cxdl and IL-2, respectively. Among these subjects, 80% (67/84) developed neutralizing antibodies against denileukin diftitox-cxdl and 13% (11/84) developed neutralizing antibodies against the IL-2 domain of denileukin diftitox-cxdl.</item>
                           <item>Treatment with LYMPHIR leads to an increase in anti-denileukin diftitox-cxdl and anti-IL-2 antibody titers. In subjects with treatment-emergent ADA during Study 302, the median anti-denileukin diftitox-cxdl antibody titers were 182, 260, 153, and 94 times higher than baseline at C2D1, C3D1, C5D1, and C8D1 and the anti-IL2 antibody titers were 2, 49, 437, and 1312 times higher than baseline at these same visits.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Anti-Drug Antibody Effects on Pharmacokinetics</content>
                        </paragraph>
                        <paragraph>The presence of ADA is associated with a reduction in the measured serum concentration. In a subset of patients with treatment-emergent anti-denileukin diftitox-cxdl and/or anti-IL-2 antibodies during Study 302, the geometric mean ratio for denileukin diftitox-cxdl C
 
  <sub>max</sub>and AUC
 
  <sub>(0-t)</sub>is 37% and 19% in Cycle 3 compared to Cycle 1, and is 30% and 15% in Cycle 5 compared to Cycle 1. The decrease in denileukin diftitox-cxdl concentration does not appear to adversely impact safety and efficacy.

 </paragraph>
                     </text>
                     <effectiveTime value="20240815"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_13_nonclintox">
               <id root="2c678496-2a32-3051-e063-6294a90a205e"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">13 </content>
                  <content styleCode="bold">NONCLINICAL TOXICOLOGY</content>
               </title>
               <text/>
               <effectiveTime value="20240117"/>
               <component>
                  <section ID="_13_1__">
                     <id root="2c678496-2a33-3051-e063-6294a90a205e"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">13.1 </content>
                        <content styleCode="bold">Carcinogenesis, Mutagenesis, Impairment of F</content>
                        <content styleCode="bold">ertility</content>
                     </title>
                     <text>
                        <paragraph>There have been no studies to assess the carcinogenic potential of denileukin diftitox-cxdl. Denileukin diftitox-cxdl showed no evidence of mutagenicity in the Ames test and the chromosomal aberration assay. There have been no studies to assess the effect of denileukin diftitox on fertility. In a 14-week repeat-dose toxicology study in rats, denileukin diftitox-cxdl caused toxicity to male reproductive organs including atrophy of the epididymis, prostate gland, and testes and single cell necrosis in the epididymis.</paragraph>
                     </text>
                     <effectiveTime value="20240117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_14_clinical">
               <id root="2c678496-2a34-3051-e063-6294a90a205e"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>
                  <content styleCode="bold">14 </content>
                  <content styleCode="bold">CLINICAL STUDIES</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Relapsed or Refractory CTCL</content>
                  </paragraph>
                  <paragraph>The efficacy of LYMPHIR was evaluated in Study 302 (NCT01871727), an open-label, single-arm, multicenter trial in patients with relapsed or refractory Stage I to IV CTCL. Eligible patients were required to have expression of CD25 on ≥ 20% of biopsied malignant cells by immunohistochemistry
 
  <content styleCode="italics">.</content>The study excluded patients with significant cardiac disease or uncontrolled infections. Patients received LYMPHIR at 9 mcg/kg as an intravenous infusion daily from Day 1 through Day 5 of each 21-day cycle. Patients continued to receive LYMPHIR until disease progression or unacceptable toxicity.

 </paragraph>
                  <paragraph>The efficacy population includes 69 patients with relapsed or refractory Stage I to III CTCL. Of the 69 patients, the median age was 64 years (range: 28 to 87 years), 65% were male, 73% were White, 19% Black or African American, 1% Asian, and 14% Hispanic or Latino. The CTCL disease stage was IA in 7%, IB in 23%, IIA in 13%, IIB in 35%, IIIA in 12%, and IIIB in 10%. The median number of prior therapies was 4 (range: 1 to 18), including both skin-directed and systemic therapies. Prior therapies included photodynamic therapy (56%), total skin electron beam therapy (42%), systemic retinoids (49%), methotrexate/pralatrexate (49%), histone deacetylase inhibitor (35%), brentuximab vedotin (26%) and mogamulizumab (12%).</paragraph>
                  <paragraph>Efficacy was established based on objective response rate (ORR), according to ISCL/EORTC Global Response Score (GRS) per Independent Review Committee (Olsen 2011). Efficacy results are shown in Table 5.</paragraph>
                  <table ID="reft_5">
                     <caption>Table 5: Efficacy Results of Study 302</caption>
                     <col width="300"/>
                     <col width="200"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">Efficacy Endpoint</content>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <content styleCode="bold">LYMPHIR</content>
                              <paragraph>
                                 <content styleCode="bold">9 mcg/kg/day </content>
                                 <content styleCode="bold">(N=69)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule"> ORR (GRS)%
    
     <sup>a</sup>
                              <br/>        (95% CI
    
     <sup>b</sup>)
   
    </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule"> 36% 
     <br/>   (25, 49)
    </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule"> Complete Response</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule"> 9%</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule"> Partial Response</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule"> 27%</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule"> Duration of Response
    
     <sup>c</sup>
                              <paragraph>      Range, months</paragraph>
                              <paragraph>      Duration ≥ 6 months, n (%)</paragraph>      Duration ≥ 12 months, n (%)
   
    </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>3.0+, 23.5+</paragraph>
                              <paragraph>13 (52%)</paragraph>5 (20%)
   
    </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <sup>a</sup>ORR, objective response rate per Olsen, et al (2011) Global Response Score (GRS), by Independent Review Committee (IRC). 
  <br/>
                     <sup>b</sup>CI, confidence interval 
  <br/>
                     <sup>c</sup>The median (95% CI) DOR using Kaplan-Meier (KM) estimate was not estimable (NE) among the 25 subjects due to censoring.

 </paragraph>
                  <paragraph>Median time to response was 1.4 months (range: 0.7 to 5.6 months).</paragraph>
                  <paragraph>Among responders, the median follow-up for duration of response was 6.5 months (range: 3.5+, 23.5+ months).</paragraph>
               </text>
               <effectiveTime value="20240816"/>
            </section>
         </component>
         <component>
            <section ID="_16_howsupplied">
               <id root="2c678496-2a35-3051-e063-6294a90a205e"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16 </content>
                  <content styleCode="bold">HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <text>
                  <paragraph styleCode="First Paragraph">
                     <content styleCode="underline">How Supplied</content>
                  </paragraph>
                  <paragraph styleCode="Paragraph">LYMPHIR (denileukin diftitox-cxdl) for injection is supplied as a sterile, white, lyophilized cake for reconstitution in a single-dose vial containing 300 mcg denileukin diftitox-cxdl. Each carton contains one vial:</paragraph>
                  <paragraph styleCode="Paragraph">NDC 52658-7777-1</paragraph>
                  <paragraph styleCode="Paragraph">
                     <content styleCode="underline">Storage and Handling</content>
                  </paragraph>
                  <paragraph>Store LYMPHIR in a refrigerator between 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. </paragraph>
               </text>
               <effectiveTime value="20240815"/>
            </section>
         </component>
         <component>
            <section ID="_17_patientinfo">
               <id root="2c678496-2a36-3051-e063-6294a90a205e"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="bold">17</content>
                  <content styleCode="bold">PATIENT COUNSELING INFORMATION</content>
               </title>
               <text>
                  <paragraph>Discuss the following with patients prior to and during treatment with LYMPHIR.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Capillary Leak Syndrome</content>
                  </paragraph>
                  <paragraph>Inform patients of the signs and symptoms of capillary leak syndrome. Advise patients to contact their healthcare provider immediately if any signs or symptoms of capillary leak syndrome occur, including edema or change in blood pressure. Instruct patients to weigh themselves daily and report weight gain
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#_5_1__">5.1</linkHtml>)]
 
  </content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Visual Impairment</content>
                  </paragraph>
                  <paragraph>Inform patients that if they experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision, or blurred vision, they should report it promptly
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#_5_2__">5.2</linkHtml>)]
 
  </content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Infusion-Related Reactions</content>
                  </paragraph>
                  <paragraph>Inform patients of the signs and symptoms of infusion-related reactions. Advise patients to contact their healthcare provider immediately if any signs or symptoms of infusion-related reaction occur, including fever, chills, breathing problems, chest pain, or hives
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#_5_3__">5.3</linkHtml>)]
 
  </content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Hepatotoxicity</content>
                  </paragraph>
                  <paragraph>Advise patients that liver enzyme elevations can occur and that they should report symptoms that may indicate liver toxicity, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#_5_4__">5.4</linkHtml>)].
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Embryo-Fetal Toxicity</content>
                  </paragraph>
                  <paragraph>Advise pregnant women and female patients of reproductive potential of the potential risk to a fetus. Advise female patients of reproductive potential to inform their healthcare provider of a known or suspected pregnancy and to use effective contraception for 7 days after the last dose
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#_5_5__">5.5</linkHtml>), Use in Specific Populations (
  
   <linkHtml href="#_8_1__">8.1</linkHtml>,
  
   <linkHtml href="#_8_3__">8.3</linkHtml>)]
 
  </content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise women not to breastfeed during treatment with LYMPHIR and for 7 days after the last dose
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#_8_2__">8.2</linkHtml>)]
 
  </content>.

 </paragraph>
                  <paragraph/>
                  <paragraph>Manufactured by: 
  <br/>  Citius Oncology, Inc. 
  <br/>  Cranford, NJ 07016 
  <br/>  US License No. 2290
 </paragraph>
                  <paragraph>LYMPHIR™ is the trademark of Citius Oncology, Inc.</paragraph>
                  <paragraph>© 2024 Citius Oncology, Inc.</paragraph>
               </text>
               <effectiveTime value="20240815"/>
            </section>
         </component>
         <component>
            <section>
               <id root="2c678496-2a37-3051-e063-6294a90a205e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
               </title>
               <text>
                  <paragraph>NDC 52658-7777-1</paragraph>
                  <paragraph>
                     <content styleCode="bold">LYMPHIR™</content>
                     <br/>
                     <content styleCode="bold">(denileukin diftitox-cxdl)</content>
                     <br/>
                     <content styleCode="bold">For Injection</content>
                     <content styleCode="bold">
                        <br/>  300 mcg/vial
  </content>
                  </paragraph>
                  <paragraph>For Intravenous Infusion 
  <br/>  After Reconstitution and Dilution. 
  <br/>  Single-dose Vial. 
  <br/>  Discard unused portion.
 </paragraph>
                  <paragraph>1 Vial       Rx Only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L4e3a8ddb-6066-45eb-827c-912b59d5b92a"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250122"/>
               <component>
                  <observationMedia ID="L4e3a8ddb-6066-45eb-827c-912b59d5b92a">
                     <text>PRINCIPAL DISPLAY PANEL (Carton) LYMPHIR (denileukin diftitox-cxdl) for injection 300 mcg/vial Rx Only (Citius Oncology)</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="citius-onco-carton-label-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>